Antengene Biologics Limited
Clinical trials sponsored by Antengene Biologics Limited, explained in plain language.
-
New hope for stomach cancer: drug combo targets tough tumors
Disease control Recruiting nowThis study tests a new drug (ATG-022) combined with pembrolizumab, with or without chemotherapy, in people with advanced stomach or gastroesophageal junction cancer that has spread. The goal is to see if the combination can shrink tumors and control the disease. Participants must…
Phase: PHASE1, PHASE2 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated May 26, 2026 09:23 UTC
-
New drug ATG 022 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called ATG 022 in 156 adults with advanced or spreading solid tumors that no longer respond to standard treatments. The main goals are to find the safest dose and to see if the drug can shrink tumors or slow their growth. The study is curre…
Phase: PHASE1 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated May 19, 2026 11:46 UTC